摘要
目的 采取丹参酮ⅡA治疗急性心肌梗死患者,检测体内血清炎症因子水平及心功能指标的变化,探讨其内在临床机制。方法 选取2014年1月~2016年1月入院治疗的急性心肌梗死患者共计80例,将患者随机分成两组（观察组与对照组）,对照组患者给予阿司匹林、低分子肝素钠、瑞替普酶等常规治疗措施,观察组患者则在对照组治疗措施的基础再给予丹参酮ⅡA,治疗1周后对比两组患者的血清炎症因子、心功能指标及不良心血管事件,即血清超敏C反应蛋白（hs-CRP）、肿瘤坏死因子α（TNF-α）及白介素6（IL-6）水平,左室射血分数（LVEF）、左室舒张末期内径（LVEDD）及舒张末期室间隔厚度（IVST）变化,两组患者心律失常心力衰竭及心源性休克等不良心血管事件出现情况。结果 患者经过治疗后观察组的血清hs-CRP、TNF-α及IL-6水平明显低于对照组,差异具有统计学意义（P〈0.05）;患者经过治疗后观察组的左室射血分数明显高于对照组,而左室舒张末期内径和舒张末期室间隔厚度则明显低于对照组,差异具有统计学意义（P〈0.05）;患者经过治疗后观察组患者心律失常发生率明显低于对照组,差异具有统计学意义（P〈0.05）;两组患者心源性休克和心力衰竭发生率对比没有明显差异,无统计学意义（P〉0.05）。结论 丹参酮ⅡA可以提高急性心肌梗死患者的心功能,有效减轻炎症反应程度,降低不良心血管事件的发生几率,使用安全可靠,值得临床推广应用。
Objective To investigate the effects of tanshinone Ⅱ A on detecting serum levels of inflammatory cytokines in the body and changes in cardiac function of patients with acute myocardial infarction, and to explore its internal clinical mechanism. Methods A total of 80 patients with acute myocardial infarction cured in our hospital from January 2014 to January 2016 were selected and randomly divided into control group and observation group with 40 cases in each. Patients in control group were given aspirin, low molecular weight heparins calcium, reteplase（rPA）, and patients in observation group were given extra tanshinone Ⅱ A on the above basis, two groups treated for one week. Serum inflammatory factors, cardiac function and adverse cardiovascular events of the two groups one week after the treatment were compared, that was hs-CRP, TNF-α, IL-6, LVEF, LVEDD, IVST, and adverse cardiovascular events such as heart failure, heart failure and cardiac shock. Results The levels of hs-CRP, TNF-α, IL-6 of observation group were significantly lower than those of control group after treatment（P 〈 0.05）. The LVEF of observation group was significantly higher than that of control group, while LVEDD and IVST of observation group were significantly higher than those of control group（P 〈 0.05）. The incidence of arrhythmia of observation group was significantly lower than that of control group（P 〈 0.05）, while heart failure and cardiogenic shock were not significant differences between the two groups（P 〉 0.05）. Conclusion Tanshinone Ⅱ A can effectively improve the cardiac function of patients with acute myocardial, effectively reduce the degree of inflammatory reaction infarction, and reduce the incidence of adverse cardiovascular events. It is safe and reliable, and it is worthy of clinical popularization and application.
出处
《中国医药科学》
2016年第17期142-145,共4页
China Medicine And Pharmacy
关键词
丹参酮ⅡA
急性心肌梗死
心功能
心血管事件
Tanshinone Ⅱ A
Acute myocardial infarction
Cardiac function
Cardiovascular events
